×

Product Pipeline

Our advanced science, patented technologies, and innovative approach to drug discovery and development has allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.

SUSTOL® for Chemotherapy-Induced Nausea and Vomiting Prevention (CINV):
U.S. FDA approved as a subcutaneous injection

CINVANTI® for CINV:
U.S. FDA approved as a 30-minute intravenous (IV) infusion and a 2-minute IV injection

ZYNRELEF for Postoperative Pain Management:

  • Marketing Applications Under Review in Canada and Approved in the U.S. and 31 European Countries

HTX-019 for Postoperative Nausea and Vomiting (PONV):

  • Bioequivalence of HTX-019 as a 30-second IV injection demonstrated to approved oral dose of aprepitant for PONV
  • The NDA for HTX-019 for PONV was submitted in November 2021.

HTX-034 for Postoperative Pain Management

Phase 2 clinical study ongoing for postoperative pain via local application into the surgical site

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.

Dev Tool:

Request: product-portfolio/pipeline
Matched Rewrite Rule: (.?.+?)(?:/([0-9]+))?/?$
Matched Rewrite Query: pagename=product-portfolio%2Fpipeline&page=
Loaded Template: page.php